Journal article
Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10
Human vaccines & immunotherapeutics, Vol.21(1), 2547432
12/2025
DOI: 10.1080/21645515.2025.2547432
PMCID: PMC12363527
PMID: 40820295
Abstract
Despite evidence highlighting benefits of age 9/10 initiation of human papillomavirus (HPV) vaccination, little is known about who is initiating the series earlier. We describe the population of children who initiate earlier and assess the relationship of earlier initiation with series completion. We used individual-level immunization registry data from Iowa which contained data on male (49.9%) and female (50.1%) children born between 2004–2013 ages 9 and 17. We compared sociodemographic characteristics using chi-square statistics and used logistic regression to assess odds of initiation. Of children with a record of HPV vaccination, only 3.2% initiated early. In comparison to children who initiated at later, the early initiator group had a higher percentage of females (
p
< .0001), greater representation of nonwhite children (
p
< .0001), higher percentage living in urban areas (
p
< .0001) and higher private insurance (
p
< .0001). In logistic regression models, earlier initiation was significantly associated with higher rates of on-time completion (OR: 10.8 (8.6, 13.5)). These results can support prioritization of efforts to promote earlier initiation. For example, rural areas may need targeted outreach. Future work could integrate geospatial analyses so that local organizations could be able to target specific counties or even zip codes with the lowest rates of initiation.
Details
- Title: Subtitle
- Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10
- Creators
- Grace W. Ryan - University of Massachusetts Chan Medical SchoolAmanda Kahl - University of IowaEmily Janio - University of IowaBethany Kintigh - Iowa Department of Public HealthDon Callaghan - Iowa Department of Public HealthNatoshia M. Askelson - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Human vaccines & immunotherapeutics, Vol.21(1), 2547432
- DOI
- 10.1080/21645515.2025.2547432
- PMID
- 40820295
- PMCID
- PMC12363527
- NLM abbreviation
- Hum Vaccin Immunother
- ISSN
- 2164-5515
- eISSN
- 2164-554X
- Publisher
- Taylor & Francis
- Grant note
- Centers for Disease Control and Prevention of the US Department of Health and Human Services: U48 DP006840-01, U48 DP006836-01, U48 DP006883-01 National Cancer Institute: P30 CA086862-24 CDC/HHSNIH/NCIU.S. Government
This work was supported by Cooperative Agreements from the Centers for Disease Control and Prevention of the US Department of Health and Human Services [#U48 DP006840-01, #1 U48 DP006836-01, #1 U48 DP006883-01]. This work was also supported by the National Cancer Institute [Grant #5 P30 CA086862-24]. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, NIH/NCI, or the U.S. Government.
- Alternative title
- G. W. RYAN ET AL
- Language
- English
- Date published
- 12/2025
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Community and Behavioral Health
- Record Identifier
- 9984948003902771
Metrics
36 Record Views